# US 2010/0168049 A1 · Combination of monosaccharides and adenosine and use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0168049 A1
- Document ID: US20100168049A1
- Status: Published application
- Kind: A1
- Application number: 12/649,367
- Filed: 2009-12-30
- Published: 2010-07-01
- Earliest claimed: 2008-12-30
- Assignees: L'oreal
- Inventors: Julien LABOUREAU; Jean-Thierry Simonnet; Pascal Portes
- Web page: https://patentgrep.com/patent/US20100168049A1

## CPC

- A61K 8/606: {Nucleosides; Nucleotides; Nucleic acids}
- A61K 8/60: Sugars; Derivatives thereof
- A61P 17/00: Drugs for dermatological disorders
- A61P 17/18: Antioxidants, e.g. antiradicals (preparations for protection against sunlight A61Q17/00)
- A61Q 19/08: Anti-ageing preparations
- A61K 2800/592: Mixtures of compounds complementing their respective functions
- A61K 2800/91: Injection
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61Q: SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS

## Abstract

The present invention relates to a composition, especially a cosmetic and/or dermatological composition, containing, in a physiologically acceptable medium, a combination of at least one monosaccharide chosen from mannose, rhamnose and a mixture thereof, and of at least one additional compound chosen from adenosine, an analogue thereof and a mixture thereof.

## Claims

### Claim 1

A composition comprising, in a physiologically acceptable medium, at least one monosaccharide chosen from mannose and rhamnose and at least one additional compound chosen from adenosine and adenosine analogues, in which the amount of said at least one additional compound is between 0.01% and 10% by weight relative to the total weight of the composition,
and in which the additional compound is chosen from adenosine, 2′-deoxyadenosine, 2′,3′-isopropylideneadenosine, toyocamycine, 1-methyladenosine, N-6-methyladenosine, adenosine N-oxide, 6-methylmercaptopurine riboside, 6-4 chloropurine riboside, phenylisopropyladenosine (PIA), 1-methylisoguanosine, N6-cyclohexyladenosine (CHA), N6-cyclopentyladenosine (CPA), 2-chloro-N6-cyclopentyladenosine, 2-chloroadenosine, N6-phenyladenosine, 2-phenylaminoadenosine, MECA, N6-phenethyladenosine, 2-p-(2-carboxyethyl)phenethylamino-5′-N-ethylcarboxamidoadenosine (CGS-21680), N-ethylcarboxamidoadenosine (NECA), 5′-(N-cyclopropyl)carboxamidoadenosine, DPMA (PD 129,944), metrifudil, erythro-9-(2-hydroxy-3-nonyl)adenine (EHNA), iodotubercidine, the compounds of formula (I):
in which:
R1 and R2, which are identical, denote a linear saturated C1-C6 or unsaturated C2-C6, or branched saturated or unsaturated C3-C6 hydrocarbon-based radical, or alternatively form, together with the oxygen atoms to which they are attached, an isopropylidene radical;
R3 denotes:
(i) a linear saturated C1-C10 or unsaturated C2-C10, or branched saturated or unsaturated C3-C10 hydrocarbon-based radical, optionally substituted with at least one group chosen from —OR′, —NR′R″, —COOR′, CONR′R″, —CF3, —F, —OCF3, —CN and —NO2, or
(ii) a group —COR4 with R4 denoting a linear saturated C1-C9 or unsaturated C2-C9, or branched saturated or unsaturated C3-C9 hydrocarbon-based radical, optionally substituted with at least one group chosen from —OR′, —NR′R″, —COOR′, —CONR′R″, —CF3, —F, —OCF3, —CN and —NO2; or
(iii) a biotin-based ester group;
R′ and R″ denoting a hydrogen atom, a linear saturated C1-C6 or unsaturated C2-C6, or branched saturated or unsaturated C3-C6 hydrocarbon-based radical, optionally substituted with at least one group chosen from —OZ, —NZZ′ and —COOZ, Z and Z′ denoting, independently of each other, a hydrogen atom or a linear saturated C1-C6 or unsaturated C2-C6, or branched saturated or unsaturated C3-C6 hydrocarbon-based radical; and
the salts, optical isomers and solvates thereof.

### Claim 2 (depends on 1)

The composition according to claim 1, further comprising at least one magnesium salt and at least one potassium salt.

### Claim 3 (depends on 2)

The composition according to claim 2, comprising magnesium sulfate.

### Claim 4 (depends on 2)

Composition according to claim 2, comprising dipotassium glycyrrhizinate.

### Claim 5 (depends on 1)

The composition according to claim 1, comprising at least one of 2′-deoxyadenosine, 2′,3′-isopropylideneadenosine, toyocamycin, 1-methyladenosine, N-6-methyladenosine, adenosine N-oxide, 6-methylmercaptopurine riboside and 6-4 chloropurine riboside.

### Claim 6 (depends on 1)

The composition according to claim 1, comprising at least one of phenylisopropyladenosine (PIA), 1-methylisoguanosine, N6-cyclohexyladenosine (CHA), N6-cyclopentyladenosine (CPA), 2-chloro-N6-cyclopentyladenosine, 2-chloroadenosine, N6-phenyladenosine, 2-phenylaminoadenosine, MECA, N6-phenethyladenosine, 2-p-(2-carboxyethyl)phenethylamino-5′-N-ethylcarboxamidoadenosine (CGS-21680), N-ethylcarboxamidoadenosine (NECA), 5′-(N-cyclopropyl)carboxamidoadenosine, DPMA (PD 129,944) and metrifudil.

### Claim 7 (depends on 1)

The composition according to claim 1, comprising at least one of erythro-9-(2-hydroxy-3-nonyl)adenine (EHNA) and iodotubercidine.

### Claim 8 (depends on 1)

The composition according to claim 1, comprising at least one compound of formula (I).

### Claim 9 (depends on 1)

The composition according to claim 1, comprising adenosine.

### Claim 10 (depends on 1)

The composition according to claim 1, in which the amount of the monosaccharide(s) is between 0.001% and 30% by weight relative to the total weight of the composition.

### Claim 11 (depends on 1)

The composition according to claim 1, wherein said composition is suitable for topical administration to the skin or its integuments, oral administration or cutaneous injection.

### Claim 12 (depends on 1)

A method, comprising applying the composition of claim 1 to human skin or its integuments.

### Claim 13 (depends on 1, 12)

The method according to claim 12, wherein said method is a method for reducing and/or preventing the characteristics of wrinkles and/or fine lines comprising applying the composition of claim 1 to human skin in need thereof.

### Claim 14

A device comprising a combination of at least one monosaccharide chosen from mannose and rhamnose and at least one additional compound chosen from adenosine and adenosine analogues, the device being capable of delivering the combination by intraepidermal and/or intradermal and/or subcutaneous injection.
